Perrigo Company plc (NYSE:PRGO) Weekly Ratings as of Apr 16, 2018

April 16, 2018 - By Theresa Judd

Perrigo Company plc (NYSE:PRGO) Corporate Logo
Big Money Sentiment increased to 1.07 in 2017 Q4. It has change of 0.28, from 2017Q3’s 0.79. The ratio is positive due to Perrigo Company plc positioning: 43 sold and 126 reduced. 73 funds acquired holdings and 107 increased holdings. Investors holded 112.10 million in 2017Q3 but now own 102.69 million shares or 8.39% less.
Jpmorgan Chase & owns 306,504 shs. Nomura Asset Limited owns 18,400 shs. Quinn Opportunity Prns Lc holds 0.17% of its capital in Perrigo Company plc (NYSE:PRGO) for 11,980 shs. Moneta Inv Advisors Lc reported 3 shs or 0% of all its holdings. Tekla Cap Mgmt Limited Com reported 0.13% in Perrigo Company plc (NYSE:PRGO). Mitsubishi Ufj Corp owns 257,020 shs. Earnest Prtn Ltd Llc reported 0% in Perrigo Company plc (NYSE:PRGO). Riverhead Capital Mgmt Llc holds 0% or 375 shs. Oppenheimer has invested 0.05% in Perrigo Company plc (NYSE:PRGO). Warren Averett Asset Mgmt Limited Liability accumulated 522 shs. Japan-based Asset Mgmt One Company Limited has invested 0.04% in Perrigo Company plc (NYSE:PRGO). Mason Street Ltd holds 18,245 shs or 0.04% of its capital. Baker Avenue Asset Mgmt Lp has 15,023 shs. Zeke Capital Ltd Liability Company owns 3,778 shs. Parnassus Invs Ca holds 0.75% or 2.21 million shs.

Perrigo Company plc (NYSE:PRGO) Ratings Coverage

In total 11 analysts cover Perrigo Company plc (NYSE:PRGO). “Buy” rating has 6, “Sell” are 0, while 5 are “Hold”. 55% are bullish. 14 are the (NYSE:PRGO)’s analyst reports since October 27, 2017 according to StockzIntelligence Inc. On Friday, December 8 the company was upgraded by Argus Research. On Monday, March 5 the rating was maintained by JP Morgan with “Neutral”. On Friday, October 27 Jefferies maintained Perrigo Company plc (NYSE:PRGO) rating. Jefferies has “Hold” rating and $71.0 target. In Tuesday, February 27 report Canaccord Genuity maintained the stock with “Buy” rating. On Monday, March 5 the stock of Perrigo Company plc (NYSE:PRGO) has “Buy” rating given by Oppenheimer. On Sunday, March 4 the rating was maintained by RBC Capital Markets with “Hold”. On Wednesday, November 15 the firm has “Buy” rating by Cantor Fitzgerald given. On Friday, November 10 the firm earned “Market Perform” rating by RBC Capital Markets. On Friday, November 10 the company was maintained by Morgan Stanley. On Friday, March 2 the rating was maintained by Cantor Fitzgerald with “Buy”. Listed here are Perrigo Company plc (NYSE:PRGO) PTs and latest ratings.

04/03/2018 Broker: RBC Capital Markets Rating: Hold New Target: $89.0 Maintain
05/03/2018 Broker: Oppenheimer Rating: Buy New Target: $98.0 Maintain
05/03/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $82 New Target: $83 Maintain
02/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $107.0 Maintain
27/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $105.0 Maintain
01/02/2018 Broker: Berenberg Rating: Buy New Target: $117 Initiates Coverage On
03/01/2018 Broker: Leerink Swann Rating: Market Perform New Target: $90 Initiates Coverage On
08/12/2017 Broker: Argus Research Old Rating: Hold New Rating: Buy Upgrade
04/12/2017 Broker: Barclays Capital Rating: Buy New Target: $93.0
15/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $107.0 Maintain

Its shares touched $81.47 on during the last trading session after 0.87% change.Currently Perrigo Company plc is uptrending after 18.43% change in last April 16, 2017. PRGO has 1.01 million shares volume. PRGO outperformed the S&P 500 by 6.88%.

Perrigo Company plc, together with its subsidiaries, develops, makes, markets, and distributes over-the-counter consumer goods and pharmaceutical products worldwide.The firm is worth $11.48 billion. It offers OTC products in various categories, including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic products, natural health and vitamins, personal care and derma-therapeutics, lifestyle, and anti-parasite; consumer healthcare products; and vitamins, minerals, and supplements.96.99 is the P/E ratio. The firm also provides generic and specialty pharmaceutical prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations.

Perrigo Company plc (NYSE:PRGO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.